| Literature DB >> 19327953 |
Andrew L Rosenberg1, Ravi S Tripathi, James Blum.
Abstract
PURPOSE: The study aimed to examine query strategies that would provide an exhaustive search method to retrieve the most referenced articles within specific categories of critical care.Entities:
Mesh:
Year: 2009 PMID: 19327953 PMCID: PMC7127294 DOI: 10.1016/j.jcrc.2008.12.010
Source DB: PubMed Journal: J Crit Care ISSN: 0883-9441 Impact factor: 3.425
Fig. 1Methods.
Specific critical care subjects
| Subject area | Search terms |
|---|---|
| Sepsis and infectious disease | “sepsis” “septic*” “nosocomial” “blood stream” |
| Mechanical ventilation and lung injury | “ventilation” “respiratory failure” “pulmonary failure” “weaning” “extubation” “ventilator” “PEEP” “positive end expiratory pressure” “noninvasive” “ARDS” “respiratory-distress” “lung injury” |
| Monitors | “hemodynamic-monitor” “CVC” “physiologic-monitor” “noninvasive-monitor” “catheter*” “central venous” “pulmonary-artery-catheter” “Swan-Ganz” “ultrasound” “Doppler” “pressure variation” |
| Mental status | “coma” “brain-damage” “brain-injury” “ICU AND delirium” “ICU AND sedation” |
| Physiologic predictors | “physiology score” “severity of illness” “severity of disease” “mortality-predict” “severity-score” |
| Organ dysfunction | “organ-failure” “organ-dysfunction” “MODS” “MSOF” |
| Resource utilization | “intensivist” “leap frog” “ICU-administration” “critical care management” “ICU management” |
| Kidney injury | “kidney-injury” “renal-failure” “dialysis” “renal-replacement-therapy” “CVVH*” “CRRT” |
| Resuscitation | “life-support” “cardiac-arrest” “cpr” “resuscitation” “cardiac massage” “cardiac-life-support” “fluid” “saline” “lactated” “albumin” “colloid” “crystalloid” |
| Shock (excluding infectious causes) | “shock” “hypoperfusion” “CHF” “heart-failure” |
| Transfusions | “transfusion” “fluid-therapy” |
⁎Denotes any form of the word preceding the symbol, i.e., septic shock, septic.
Most cited articles in critical care medicine by subject
| Overall Citation Rank |
|---|
| A. Sepsis/systemic inflammatory response syndrome (no. of times cited) |
| 1. (#6) Tracey, KJ et al. Anti-cachectin TNF monoclonal-antibodies prevent septic shock during lethal bacteremia. |
| 2. (#7) Bone, RC et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. |
| 3. (#8) Bernard, GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. |
| 4. (#10) Bone, RC et al. American-College of Chest Physicians Society of Critical Care Medicine Consensus Conference—definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. |
| 5. (#12) Van den Berghe, G et al. Intensive insulin therapy in critically ill patients. |
| 6. (#19) Ziegler, EJ et al. Treatment of gram-negative bacteremia and septic shock with HA-1a human monoclonal-antibody against endotoxin—a randomized, double-blind, placebo-controlled trial. |
| 7. (#22) Angus, DC et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. |
| 8. (#25) Bone, RC. The pathogenesis of sepsis. |
| 9. (#28) Waage, A et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock—association between interleukin-6, interleukin-1, and fatal outcome. |
| 10. (#31) Wichterman, KA et al. Sepsis and septic shock—a review of laboratory models and a proposal. |
| 11. (#34) Bone, RC et al. A controlled clinical-trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. |
| 12. (#37) Parrillo, JE. Mechanisms of disease—pathogenetic mechanisms of septic shock. |
| 13. (#41) Annane, D et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. |
| 14. (#43) Petros, A et al. Effect of nitric-oxide synthase inhibitors on hypotension in patients with septic shock. |
| 15. (#52) Cannon, JG et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. |
| 16. (#55) Casey, LC et al. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. |
| 17. (#56) Vanzee, KJ et al. Tumor-necrosis-factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor-necrosis-factor–alpha in vitro and in vivo. |
| 18. (#59) Hack, CE et al. Increased plasma-levels of interleukin-6 in sepsis. |
| 19. (#62) Moore, FA et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications—the results of a metaanalysis. |
| 20. (#64) Lowenstein, CJ et al. Nitric-oxide—a physiological messenger. |
| 21. (#69) Fry, DE et al. Multiple system organ failure—role of uncontrolled infection. |
| 22. (#70) Parker, MM et al. Profound but reversible myocardial depression in patients with septic shock. |
| 23. (#72) Kudsk, KA et al. Enteral versus parenteral-feeding—effects on septic morbidity after blunt and penetrating abdominal-trauma. |
| 24. (#75) Fisher, CJ et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. |
| 25. (#77) Hotchkiss, RS et al. Medical progress: the pathophysiology and treatment of sepsis. |
| 26. (#78) Greenman, RL et al. A controlled clinical-trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. |
| 27. (#81) Martin, GS et al. The epidemiology of sepsis in the United States from 1979 through 2000. |
| 28. (#83) Glauser, MP et al. Septic shock—pathogenesis. |
| 29. (#89) Dellinger, RP et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. |
| 30. (#94) Bone, RC et al. Sepsis syndrome—a valid clinical entity. |
| 31. (#96) Fisher, CJ et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome—results from a randomized, double-blind, placebo-controlled trial. |
| 32. (#97) Parrillo, JE et al. Septic shock in humans—advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. |
| 33. (#105) Assicot, M et al. High serum procalcitonin concentrations in patients with sepsis and infection. |
| 34. (#109) Ochoa, JB et al. Nitrogen-oxide levels in patients after trauma and during sepsis. |
| 35. (#114) Moore, FA et al. TEN versus TPN following major abdominal-trauma–reduced septic morbidity. |
| 36. (#120) Abraham, E et al. Efficacy and safety of monoclonal-antibody to human tumor necrosis-factor–alpha in patients with sepsis syndrome—a randomized, controlled, double-blind, multicenter clinical-trial. |
| 37. (#121) Meakins, JL et al. Delayed-hypersensitivity—indicator of acquired failure of host defenses in sepsis and trauma. |
| 38. (#122) Pinsky, MR et al. Serum cytokine levels in human septic shock—relation to multiple system organ failure and mortality. |
| 39. (#131) Danner, RL et al. Endotoxemia in human septic shock. |
| 40. (#132) Eickhoff, TC et al. Neonatal sepsis + other infections due to group b beta-hemolytic streptococci. |
| 41. (#134) Wheeler, AP et al. Treating patients with severe sepsis. |
| 42. (#151) Sprung, CL et al. The effects of high-dose corticosteroids in patients with septic shock—a prospective, controlled-study. |
| 43. (#153) Damas, P et al. Cytokine serum level during severe sepsis in human il-6 as a marker of severity. |
| 44. (#157) Askanazi, J et al. Influence of total parenteral-nutrition on fuel utilization in injury and sepsis. |
| 45. (#162) Docke, WD et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. |
| 46. (#168) Petros, A et al. Effects of a nitric-oxide synthase inhibitor in humans with septic shock. |
| 47. (#173) BrunBuisson, C et al. Incidence, risk-factors, and outcome of severe sepsis and septic shock in adults—a multicenter prospective-study in intensive-care units. |
| 48. (#174) Nava, E et al. Inhibition of nitric-oxide synthesis in septic shock—how much is beneficial. |
| 49. (#178) Szabo, C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. |
| 50. (#180) Warren, BL et al. High-dose a randomized antithrombin III in severe sepsis—a randomized controlled trial. |
| 51. (#181) Bone, RC. Sir Isaac Newton, Sepsis, SIRS, and cars. |
| 52. (#182) Schumer, W. Steroids in treatment of clinical septic shock. |
| 53. (#183) Damas, P et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. |
| 54. (#185) Cohen, J et al. The immunopathogenesis of sepsis. |
| 55. (#187) Rush, BF et al. Endotoxemia and bacteremia during hemorrhagic-shock—the link between trauma and sepsis. |
| 56. (#190) Fourrier, F et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation—compared patterns of antithrombin-III, protein-C, and protein-S deficiencies. |
| 57. (#192) Munoz, C et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. |
Article's rankings listed by subgroup then by its position within the overall top 200 citations.